Frontiers in Oncology (Feb 2023)

Case report: PSMA PET/CT addresses the correct diagnosis in a patient with metastatic prostate cancer despite negative core biopsies and mpMRI. A diagnostic challenge

  • Luigia Vetrone,
  • Giulia Cuzzani,
  • Riccardo Mei,
  • Lucia Zanoni,
  • Alessandro Bertaccini,
  • Lorenzo Bianchi,
  • Paolo Castellucci,
  • Caterina Gaudiano,
  • Alberta Cappelli,
  • Francesca Giunchi,
  • Stefano Fanti,
  • Stefano Fanti

DOI
https://doi.org/10.3389/fonc.2023.1101221
Journal volume & issue
Vol. 13

Abstract

Read online

This is a case of [68 Ga]Ga-Prostate-specific membrane antigen (PSMA)-11 PET/CT in a 73-years old patient presenting high Prostate Specific Antigen (PSA) levels despite both multi-parametric magnetic resonance imaging (mpMRI) and 12-core saturation biopsy negative for prostate cancer (Pca). This is a highly interesting case because, despite the advanced metastatic spread at initial presentation as showed by [68Ga]Ga-PSMA-PET/CT, the primary Pca was detected by none of the diagnostic techniques (12 random sample biopsy, mpMRI, PSMA PET/CT). However, [68Ga]Ga-PSMA-PET/CT showed a suspicious axillary lesion suitable for biopsy, which finally resulted as Pca metastasis. This case report is therefore a brilliant example of how [68Ga]Ga-PSMA-PET/CT optimized patient’s management.

Keywords